A combination therapy that adds a recently approved drug to the current standard of care for newly diagnosed acute myeloid ...

VANFLYTA (quizartinib) has been approved by Health Canada for use in combination with standard cytarabine and anthracycline ...

DUBLIN, Feb. 15, 2018 /PRNewswire/ -- The 'Acute Myeloid Leukemia Pricing, Reimbursement, and Access' report has been added to ResearchAndMarkets.

The approval of Tibsovo was based on an open-label, single-arm, multicenter clinical trial (Study AG120-C-001) involving 174 patients with relapsed or refractory AML with an IDH1 miutation.

Pfizer announced that the Food and Drug Administration (FDA) has approved Daurismo (glasdegib) tablets for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adults aged ≥75 years ...

The U.S. Food and Drug Administration today approved Daurismo (glasdegib) tablets to be used in combination with low-dose cytarabine (LDAC), a type of chemotherapy, for the treatment of newly ...